Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Ophthalmology

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Dry Eye Disease Clinical Trials

A listing of Dry Eye Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (5) clinical trials

The objective of this study is to evaluate the efficacy and safety of two strengths of Lacripep™ ophthalmic solution versus placebo administered 3 times a day for 4 weeks with subjects with Dry Eye associated with Primary Sjögren’s Syndrome


Assess the Safety and Efficacy of CsA Ophthalmic Gel in Subjects With Dry Eye

A multicenter, randomized, single-blind, positive controlled exploratory study will be conducted with cyclosporine A ophthalmic emulsion as the control drug. The experimental drugs were divided into three groups: Treatment group A: CsA eye gel: 0.3 g: 0.15 mg, once daily Treatment group B: CsA eye gel: 0.3 g: 0.15 mg, ...


A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED)

AZ201801 is a multicenter, double-masked, vehicle-controlled, randomized, parallel group study carried out in 2 sequentially overlapping cohorts evaluating the safety, efficacy and tolerability of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD) and evaporative Dry Eye Disease (DED)


A Multi-Center Randomized Double-Masked Parallel-Group Vehicle-Controlled Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease

A Multi-Center, Phase 2, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% Novel Formulation) Compared to Vehicle in Subjects with Dry Eye Disease


Effects of RP101 in Post-menopausal Women With Dry Eye Syndrome

Redwood Pharma is developing the novel ophthalmic product RP101 containing the known active substance 17-oestradiol-3-phosphate and based upon the drug delivery platform IntelliGel which controls the active substance release. The novel formulation is planned to meet the still unmet medical need of an efficacious treatment against chronic dry eye in ...